Investigating cognitive impairment in young cancer patients during and after chemotherapy
A Multidisciplinary Neuroscience Approach to Investigate Cognitive Impairment in Young Patients With Cancer Prospectively
This study is testing how chemotherapy affects memory and attention in children and young adults with cancer to better understand their cognitive challenges during and after treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 7 Years to 29 Years |
| Sex | All |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Drugs / interventions | chemotherapy, methotrexate |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT05840575 on ClinicalTrials.gov |
What this trial studies
The MyBrain study examines the cognitive function of children, adolescents, and young adults undergoing chemotherapy for cancer. It assesses cognitive skills such as memory and attention, brain electrical activity through electroencephalograms, and biological markers related to brain function. The study aims to understand the patterns of cognitive impairment associated with chemotherapy and how these may affect patients over time. By comparing patients with matched controls, the research seeks to provide insights into the cognitive challenges faced by young cancer patients.
Who should consider this trial
Good fit: Ideal candidates are newly diagnosed patients aged 7-29 years with non-CNS cancer who will undergo chemotherapy.
Not a fit: Patients with severe intellectual disabilities, mental health disorders, or those who have had previous chemotherapy or radiotherapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of cognitive impairment in young cancer patients, enhancing their quality of life.
How similar studies have performed: Other studies have indicated cognitive impairment in cancer patients, but this specific approach focusing on young patients during chemotherapy is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients who are newly diagnosed with a non-CNS cancer and will undergo chemotherapy at University Hospital Copenhagen, Rigshospitalet. * At the age of 7-29 years at diagnosis * Each patient is matched (1:1) with a control participant within 24 months of age. The controls are recruited from the patient's own social circle and can be a friend, partner, or close family (sibling or cousin). Exclusion Criteria: * Unable to speak and understand Danish * Severe intellectual disability or mental health disorder that hinders participation * Brain metastases, * Terminal illness * Have had a previous chemotherapy or radiotherapy treatment
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Study coordinator: Lisa L Hjalgrim, PhD, MD
- Email: lisa.lyngsie.hjalgrim@regionh.dk
- Phone: +4535450962
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.